Cambridge Nutritional Sciences plc (CNSL) Fair Value & Analysis
Healthcare · GB · Market cap 4.1M GBX
Fair value as of: Jul 12, 2026
From 8 valuation models · updated 29 days ago
Share price +5.7% over the past month.
A solid business, screening 62% undervalued on our models.
What matters now
- The price is below even our cautious bear case (£0.0232). The market is more pessimistic than our downside scenario.
- Solid quality (52/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.
How to read this chart
60‑month range £0.0163 – £0.6905 · fair‑value band £0.0232 – £0.0319 · the £0.0175 price screens below the £0.0284 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 12, 2026.
Analysis
Cambridge Nutritional Sciences plc (CNSL) currently trades at £0.0175, while our model-based Fair Value estimate is £0.0284, implying the stock looks roughly 62.3% undervalued today. The Quality Score stands at 52/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Cambridge Nutritional Sciences plc generated revenue of £8.1M at a net margin of 16.9%. Revenue declined 6.6% year over year. It earns a return on equity of 13.3%. The balance sheet holds a net cash position of £4.5M. Fundamentals as of Jul 12, 2026
Our scenario range runs from £0.0232 (bear case) to £0.0319 (bull case); at £0.0175, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 62%, CNSL screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 8 models by family
Widest divergence: Multiples (£0.1100) versus Asset-Based (£0.0300). Highest evidence: Growth-Adj P/E (68).
Notify me when CNSL reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 52 · Market factors (momentum, volatility) 17
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Cambridge Nutritional Sciences plc, together with its subsidiaries, develops, manufactures, and distributes medical diagnostics products for the food sensitivity testing market. The company is involved in the research, development, and production of kits for detection of immune reactions to food under the FoodPrint brand.
Full company description
Cambridge Nutritional Sciences plc, together with its subsidiaries, develops, manufactures, and distributes medical diagnostics products for the food sensitivity testing market. The company is involved in the research, development, and production of kits for detection of immune reactions to food under the FoodPrint brand. It also provides clinical analysis to the general public, clinics, and health professionals; and supplies Food Detective, a food sensitivity test. In addition, the company offers My Health Tracker, a health app for tracking symptoms, accessing FoodPrint results, and managing gut health; and CNS Lab, which provides laboratory services for food sensitivity. It serves the government, private hospitals and clinics, reference laboratories, nutritionists, naturopaths, consumers, and functional medicine healthcare practitioners in the United Kingdom, rest of Europe, North America, South/Central America, India, rest of Asia and the Far East, Africa, and the Middle East. The company was formerly known as Omega Diagnostics Group PLC and changed its name to Cambridge Nutritional Sciences plc in September 2023. Cambridge Nutritional Sciences plc is based in London, the United Kingdom.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Cambridge Nutritional Sciences plc reported revenue of £8.3M in FY2025 versus £6.8M in FY2021, a compound +5.1%/yr. Reported net income was £1.6M in FY2025.
Watch CNSL: get an alert when its fair value changes →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 35/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare Cambridge Nutritional Sciences plc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Cambridge Nutritional Sciences plc (CNSL) overvalued or undervalued?
What is the fair value of CNSL?
What is the quality score of CNSL?
What is the revenue of Cambridge Nutritional Sciences plc (CNSL)?
What is the net profit margin of CNSL?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Cambridge Nutritional Sciences plc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.